118.46 USD
▲+3.29+6.11%
2026-08-03
市值
$793.54M
市盈率
—
EPS
-1.92
股息率
—
52 周区间
29.18 – 116.69
成交量
215.09K
Beta
1.47
目标价
116.85
52W 低 29.1852W 高 116.69
价格走势
公司简介
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging ...